Patent ID: 7435415

Claim:
A method of inhibiting growth of or killing small cell lung cancer (SCLC) cells in a patient in need thereof comprising administering to said patient a monoclonal antibody or antigen binding fragment thereof wherein said monoclonal antibody is selected from the group consisting of: a) a monoclonal antibody produced from the hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2360 (MoAb 51.2), PTA-2357 (MoAb 109.12), PTA-2358 (MoAb 37.14), or PTA-2359 (MoAb 26.1); b) a monoclonal antibody which specifically recognizes an epitope of an antigen present on the surface of SCLC cells, said antigen being a glycosylated single polypeptide having a molecular weight of about 200 kDa as determined by SDS-PAGE under reducing conditions that is absent from human multiple myeloma cells and the epitope of the antigen is recognizable by a monoclonal antibody produced from the hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2360 (MoAb 51.2), PTA-2357 (MoAb 109.12), or PTA-2358 (MoAb 37.14), c) a monoclonal antibody which specifically recognizes an epitope of an antigen present on the surface of SCLC cells, said antigen being a glycosylated polypeptide comprising two chains or fragments closely related in mass having a molecular weight of about 35 kDa-50 kDa as determined by SDS-PAGE under reducing conditions that is absent from human multiple myeloma cells and neuroendocrine cells and the epitope of the antigen is recognizable by a monoclonal antibody produced from the hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2358 (MoAb 37.14); and d) a monoclonal antibody which specifically recognizes an epitope of an antigen present on the surface of SCLC cells as assayed by FACS analysis, said antigen being intact and not denatured, degraded, linearized, or otherwise adversely affected and the epitope of the antigen is recognizable by a monoclonal antibody produced from the hybridoma cell line deposited at the American Type Culture Collection (ATCC) having ATCC Accession No. PTA-2359 (MoAb 26.1).